Activated protein C resistance and thrombosis: Molecular mechanisms of hypercoagulable state due to FVR506Q mutation

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue 3, 1999, Pages 273-289

  Dahlbäck, Björn ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

APC resistance; Factor V; Factor V Leiden; Familial thrombosis; Protein C

Indexed keywords

ACTIVATED PROTEIN C RESISTANCE; CONFERENCE PAPER; DISEASE ASSOCIATION; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; HYPERCOAGULABILITY; INCIDENCE; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RACE DIFFERENCE; RISK FACTOR; THROMBOPHILIA; THROMBOSIS;

EID: 0032770492     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-994931     Document Type: Conference Paper

References (188)

1. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: Initiation, maintenance, and regulation. Biochemistry 1991;30:10363-10370
2. Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 1995;74:1-6
3. Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992;326:800-806
4. Nemerson Y. The tissue factor pathway of blood coagulation. Semin Hematol 1992;29:170-176
5. Mann KG, Lorand L. Introduction: Blood coagulation. Methods Enzymol 1993;222:1-10
6. Wu KK, Thiagarajan P. Role of endothelium in thrombosis and hemostasis. Annu Rev Med 1996;47:315-331
7. Bombeli T, Mueller M, Haeberli A. Anticoagulant properties of the vascular endothelium. Thromb Haemost 1997;77:408-423
8. Bauer KA, Rosenberg RD. Role of antithrombin III as a regulator of in vivo coagulation. Semin Hematol 1991;28:10-18
9. Lindahl U, Lidholt K, Spillmann D, Kjellen L. More to "heparin" than anticoagulation. Thromb Res 1994;75:1-32
10. Esmon CT The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989;264:4743-4746
11. Dahlbäck B. The protein C anticoagulant system: Inherited defects as basis for venous thrombosis. Thromb Res 1995;77:1-43
12. Esmon CT. Molecular events that control the protein C anticoagulant pathway. Thromb Haemost 1993;70:29-35
13. Dahlbäck B, Stenflo J. High molecular weight complex in human plasma between vitamin K-dependent protein S and complement component C4b-binding protein. Proc Natl Acad Sci USA 1981;78:2512-2516
14. Dahlbäck B. Protein S and C4b-binding protein: Components involved in the regulation of the protein C anticoagulant system. Thromb Haemost 1991;66:49-61
15. Dahlbäck B. Inhibition of protein Ca cofactor function of human and bovine protein S by C4b-binding protein. J Biol Chem 1986;261:12022-12027
16. Heeb MJ, Mesters RM, Tans G, Rosing J, Griffin JH. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem 1993;268:2872-2877
17. Hackeng TM, van 't Veer C, Meijers JC, Bouma BN. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem 1994;269:21051-21058
18. Shen L, Dahlbäck B. Factor V and protein S as synergistic co-factors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994;269:18735-18738
19. Dahlbäck B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 1994;91:1396-1400
20. Kalafatis M, Krishnaswamy S, Rand MD, Mann KG. Factor V. Methods Enzymol 1993;222:224-236
21. Mann KG, Krishnaswamy S, Lawson JH. Surface-dependent hemostasis. Semin Hematol 1992;29:213-226
22. Rosing J, Tans G. Coagulation factor V: An old star shines again. Thromb Haemost 1997;78:427-433
23. Fay PJ. Factor VIII structure and function. Thromb Haemost 1993;70:63-67
24. Kane WH, Davie EW. Blood coagulation factors V and VIII: Structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood 1988;71:539-555
25. Pemberton S, Lindley P, Zaitsev V, et al. A molecular model for the triplicated A-domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood 1997;89:2413-2421
26. Zaitseva I, Zaitsev V, Card G. et al. The X-ray structure of human serum ceruloplasmin at 3.1 Å: Nature of the copper centres. J Biol Inorg Chem 1996;1:15-23
27. Villoutreix BO, Dahlbäck B. Structural investigation of the A domains of human blood coagulation factor V by molecular modeling. Protein Sci 1998;7:1-9
28. Baumgartner S, Hofmann K, Chiquet-Ehrismann R, Bucher P. The discoidin domain family revisited: New members from prokaryotes and a homology-based fold prediction. Protein Sci 1998;7:1626-1631
29. Villoutreix BO, Bucher P, Hofmann K, Baumgartner S, Dahlbäck B, Molecular models for the two discoidin domains of human blood coagulation factor V. J Mol Model 1998;4:268-275
30. Thorelli F., Kaufman RJ, Dahlbäck B. Cleavage requirements for activation of factor V by factor Xa. Eur J Biochem 1997;247:12-20
31. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994;269:31869-31880
32. Nicolaes GA, Tans G, Thomassen MC, et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995;270:21158-21166
33. Rosing J, Hoekema L, Nicolaes GA, et al. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995;270:27852-27858
34. Heeb MJ, Kojima Y, Hackeng TM, Griffin JH. Binding sites for blood coagulation factor Xa and protein S involving residues 493-506 in factor Va. Protein Sci 1996;5:1883-1889
35. Solymoss S, Tucker MM, Tracy PB. Kinetics of inactivation of membrane-bound factor Va by activated protein C. Protein S modulates factor Xa protection. J Biol Chem 1988;263:14884-14890
36. Walker FJ. Regulation of activated protein C by protein S. The role of phospholipid in factor Va inactivation. J Biol Chem 1981;256:11128-11131
37. He X, Shen L, Villoutreix BO, Dahlbäck B. Amino acid residues in thrombin-sensitive region and first epidermal protein S determining specificity of the activated protein C cofactor function. J Biol Chem 1998;273:27449-27458
38. Krishnaswamy S, Williams EB, Mann KG. The binding of activated protein C to factors V and Va J Biol Chem 1986;261:9684-9693
39. Yegneswaran S, Wood GM, Esmon CT, Johnson AE. Protein S alters the active site location of activated protein C above the membrane surface. A fluorescence resonance energy transfer study of topography. J Biol Chem 1997;272:25013-25021
40. Fay PJ, Smudzin TM, Walker FJ. Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. Identification of cleavage sites and correlation of proteolysis with cofactor activity. J Biol Chem 1991;266:20139-20145
41. Regan LM, Lamphear BJ, Huggins CF, Walker FJ, Fay PJ. Factor IXa protects factor VIIIa from activated protein C. Factor IXa inhibits activated protein C-catalyzed cleavage of factor VIIIa at Arg562. J Biol Chem 1994;269:9445-9452
42. Koedam JA, Meijers JC, Sixma JJ, Bouma BN. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 1988;82:1236-1243
43. Fay PJ, Coumans JV, Walker FJ. Von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation. J Biol Chem 1991;266:2172-2177
44. Thorelli E, Kaufman RJ, Dahlbäck B. Cleavage of factor V at Arg506 by activated protein C and the expression of anticoagulent activity of factor V. Blood 1999;93:2552-2558
45. Thorelli E, Kaufman RJ, Dahlbäck B. The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V. J Biol Chem 1998;273:16140-16145
46. Varadi K, Rosing J, Tans G, et al. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: Influence of the factor VR506Q mutation. Thromb Haemost 1996;76:208-214
47. de Fouw NJ, van Tilburg NH, Haverkate F, Bertina RM. Activated protein C accelerates clot lysis by virtue of its anticoagulant activity. Blood Coagul Fibrinolysis 1993;4:201-210
48. Bajzar L. Nesheim M. The effect of activated protein C on fibrinolysis in cell-free plasma can be attributed specifically to attenuation of prothrombin activation. J Biol Chem 1993;268:8608-8616
49. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995;270:14477-14484
50. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996;88:2093-2100
51. Nordström M. Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992;232:155-160
52. Anderson FAJ. Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933-938
53. Malm J, Laurell M, Nilsson IM, Dahlbäck B. Thromboembolic disease - Critical evaluation of laboratory investigation [see comments]. Thromb Haemost 1992;68:7-13
54. Dahlbäck B. Resistance to activated protein C as risk factor for thrombosis: Molecular mechanisms, laboratory investigation, and clinical management. Semin Hematol 1997;34:217-234
55. Dahlbäck B. Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis. Thromb Haemost 1997;78:483-488
56. Bertina RM. Introduction: Hypercoagulable states. Semin Hematol 1997;34:167-170
57. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-3703
58. Reitsma PH. Protein C deficiency: From gene defects to disease. Thromb Haemost 1997;78:344-350
59. Aiach M, Borgel D, Gaussem P, et al. Protein C and protein S deficiencies. Semin Hematol 1997;34:205-216
60. Borgel D, Gandrille S, Aiach M, Protein S deficiency. Thromb Haemost 1997;78:351-356
61. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: Part 2. Thromb Haemost 1996;76:824-834
62. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: Part I. Thromb Haemost 1996;76:651-662
63. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C [see comments]. Proc Natl Acad Sci USA 1993;90:1004-1008
64. Dahlbäck B. Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene. Haemostasis 1994;24:139-151
65. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C [see comments]. Nature 1994;369:64-67
66. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosisprone families with inherited resistance to activated protein C. J Clin Invest 1994;94:2521-2524
67. Voorberg J, Roelse J, Koopman R, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V [see comments]. Lancet 1994;343:1535-1536
68. Greengard JS, Sun X, Xu X, et al. Activated protein C resistance caused by Arg506Gln mutation in factor Va [letter]. Lancet 1994;343:1361-1362
69. Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis [see comments]. Lancet 1994;343:1536-1538
70. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients [see comments]. Blood 1993;82:1989-1993
71. Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study [see comments]. Lancet 1993;342:1503-1506
72. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis [see comments]. N Engl J Med 1994;330:517-522
73. Halbmayer WM, Haushofer A, Schon R, Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects [see comments]. Blood Coagul Fibrinolysis 1994;5:51-57
74. Zöller B, Norlund L, Leksell H, et al. High prevalence of the FVR506Q mutation causing APC resistance in a region of southern Sweden with a high incidence of venous thrombosis [letter]. Thromb Res 1996;83:475-477
75. Schroder W, Koesling M, Wulff K, Wehnert M, Herrmann FH. Large-scale screening for factor V Leiden mutation in a north-eastern German population. Haemostasis 1996;26:233-236
76. Chaida C, Gialeraki A, Tsoukala C, Mandalaki T. Prevalence of the FVQ506 mutation in the Hellenic population [letter]. Thromb Haemost 1996;76:127
77. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden [see comments]. Lancet 1995;346:1133-1134
78. Larsen TB, Lassen JF, Brandslund I, et al. The Arg506Gln mutation (FV Leiden) among a cohort of 4188 unselected Danish newborns. Thromb Res 1998;89:211-215
79. Seligsohn U, Zivelin A. Thrombophilia as a multigenic disorder. Thromb Haemost 1997;78:297-301
80. Dzimiri N, Meyer B. World distribution of factor V Leiden [letter; comment]. Lancet 1996;347:481-482
81. Beauchamp NJ, Daly ME, Hampton KK, et al. High prevalence of a mutation in the factor V gene within the U.K. population: Relationship to activated protein C resistance and familial thrombosis. Br J Haematol 1994;88:219-222
82. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 1997; 277:1305-1307
83. Mari D, Mannucci PM, Duca F, Bertolini S, Franceschi C. Mutant factor V (Arg506Gln) in healthy centenarians [letter]. Lancet 1996;347:1044
84. Pepe G, Rickards O, Vanegas OC, et al. Prevalence of factor V Leiden mutation in non-European populations. Thromb Haemost 1997;77:329-331
85. Ko YL, Hsu TS, Wu SM, et al. The G1691A mutation of the coagulation factor V gene (factor V Leiden) is rare in Chinese: An analysis of 618 individuals, Hum-Genet 1996;98:176-177
86. Chan LC, Bourke C, Lam CK, et al. Lack of activated protein C resistance in healthy Hong Kong Chinese blood donors - correlation with absence of Arg506-Gln mutation of factor V gene [letter]. Thromb Haemost 1996;75:522-523
87. Shen MC, Lin JS, Tsay W. High prevalence of antithrombin III, protein C and protein S deficiency, but no factor V Leiden mutation in venous thrombophilic Chinese patients in Taiwan. Thromb Res 1997;87:377-385
88. Zama T, Murata M, Ono F, et al. Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Japanese patients with various forms of thrombosis, and normal individuals. Int J Hematol 1996;65:71-78
89. Kodaira H, Ishida F, Shimodaira S, et al. Resistance to activated protein C and Arg 506 Gln factor V mutation are uncommon in eastern Asian populations. Acta Haematol 1997;98:22-25
90. Soubrier F. Fery I, Verdy E, et al. The frequency of the factor V gene R506Q mutation varies between regions of France [letter]. Nouv Rev Fr Hematol 1995;37:175
91. Lindqvist PG, Svensson PJ, Dahlbäck B, Marsal K. Factor V R506Q mutation (activated protein C resistance) associated with reduced intrapartum blood loss - A possible evolutionary selection mechanism. Thromb Haemost 1998;79:69-73
92. Cox MJ, Rees DC, Martinson JJ, Clegg JB. Evidence for a single origin of factor V Leiden. Br J Haematol 1996;92:1022-1025
93. Zöller B, Hillarp A, Dahlbäck B. Activated protein C resistance caused by a common factor V mutation has a single origin. Thromb Res 1997;85:237-243
94. Zivelin A, Griffin JH, Xu X, et al. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood 1997;89:397-402
95. Inbal A, Griffin JH, Xu X, et al. Extensive venous and arterial thrombosis in a patient with familial APC resistance without R506Q mutation. Blood 1997;90(Suppl. 1):150a
96. Simioni P, Girolami A. Homozygous factor V-deficient patients show resistance to activated protein C whereas heterozygotes do not. Blood Coagul Fibrinolysis 1994;5:825-827
97. Simioni P, Scudeller A, Radossi P, et al. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: Report of two cases belonging to two unrelated kindreds. Thromb Haemost 1996;75:422-426
98. Bernardi F, Faioni EM, Castoldi E, et al. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997;90:1552-1557
99. Lunghi B, Iacoviello, L, Gemmati D, et al. Detection of new polymorphic markers in the factor V gene: Association with factor V levels in plasma. Thromb Haemost 1996;75:45-48
100. Bokarewa MI, Falk G, Bremme K, Blombäck M, Wiman B. Search for mutations in the genes for coagulation factors V and VIII with a possible predisposition to activated protein C resistance. Eur J Clin Invest 1997;27:340-345
101. Amano K, Michnick DA, Mousalli M, Kaufman RJ. Mutation in either Arg336 or Arg562 in factor VIII is insufficient for complete resistance to activated protein C (APC)-mediated inactivation: Implications for the APC resistance test. Thromb Haemost 1998;79:557-563
102. Williamsson D, Brown K, Luddington R, Baglin C, Baglint T. A new mutation (Arg306Thr) associated with resistance to activated protein C. Blood 1998;91:1140-1144
103. Chan WP Lee CK, Kwong YL, Lam CK, Liang R. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 1998;91;1135-1139
104. Aparicio C, Dahlbäck B. Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene. Biochem J 1996;313:467-472
105. Heeb MJ, Kojima Y, Greengard JS, Griffin JH. Activated protein C resistance: Molecular mechanisms based on studies using purified Gln506-factor V. Blood 1995;85:3405-3411
106. Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor VR506Q. J Biol Chem 1995;270:4053-4057
107. Simioni P. Scarano L, Gavasso S, et al. Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation. Br J Haematol 1996;92:435-441
108. Zöller B, Hohm J, Svensson P, Dahlbäck B. Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency. Thromb Haemost 1996;75:270-274
109. Shen L, He X, Dahlbäck B. Synergistic cofactor function of factor V and protein S to activated protein C in inactivation of factor VIIIa. Thromb Haemost 1997;78:1030-1036
110. Lu D, Kalafatis M, Mann KG, Long GL. Comparison of activated protein C/protein S-mediated inactivation of human factor VIII and factor V. Blood 1996;87:4708-4717
111. Dahlbäck B, Carlsson M. Factor VIII defect associated with familial thrombophilia. Thromb Haemost 1991;65:658 (abstract)
112. Bajzar L, Kalafatis M, Simioni P, Tracy PB. An antifibrinolytic mechanism describing the prothrombotic effect associated with factor V Leiden. J Biol Chem 1996;271:22949-22052
113. Dahlbäck B. Resistance to activate protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons [see comments]. Thromb Haemost 1995;73:739-742
114. Jorquera JI, Montoro JM, Fernandez MA, Aznar JA, Aznar J. Modified test for activated protein C resistance [letter] [see comments]. Lancet 1994;344:1162-1163
115. Trossaert M, Conard J, Horellou MH, et al. Modified APC resistance assay for patients on oral anticoagulants [letter; comment]. Lancet 1994;344:1709
116. Svensson PJ, Zöller B, Dahlbäck B. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls. Thromb Haemost 1997;77:332-335
117. Varadi K, Moritz B, Lang H, et al. A chromogenic assay for activated protein C resistance. Br J Haematol 1995;90:884-891
118. Nicolaes GA, Thomassen MC, van Oerle R, et al. A prothrombinase-based assay for detection of resistance to activated protein C. Thromb Haemost 1996;76:404-410
119. Le DT, Griffin JH, Greengard JS, Mujumdar V, Rapaport SI. Use of a generally applicable tissue factor - Dependent factor V assay to detect activated protein C-resistant factor Va in patients receiving warfarin and in patients with a lupus anticoagulant. Blood 1995;85:1704-1711
120. Dahlbäck B, Hillarp A, Rosen S, Zöller B. Resistance to activated protein C, the FV: Q506 allele, and venous thrombosis. Ann Hematol 1996;72:166-176
121. Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men [see comments]. N Engl J Med 1995;332:912-917
122. Svensson PJ, Zöller B, Mattiasson I, Dahlbäck B. The factor VR506Q mutation causing APC resistance is highly prevalent amongst unselected outpatients with clinically suspected deep venous thrombosis. J Intern Med 1997;241:379-385
123. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosisprone families with inherited resistance to activated protein C. J Clin Invest 1994;94:2521-2524
124. Hillarp A, Dahlbäck B, Zöller B. Activated protein C resistance: From phenotype to genotype and clinical practice. Blood Rev 1995;9:201-212
125. Desmarais S, de Moerloose P, Reber G, et al. Resistance to activated protein C in an unselected population of patients with pulmonary embolism. Lancet 1996;347:1374-1375
126. Manten B, Westendorp RG, Koster T, Reitsma PH, Rosendaal FR. Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: A focus on the factor V Leiden mutation. Thromb Haemost 1996;76:510-513
127. Martinelli I, Cattanco M, Panzeri D, Mannucci PM. Low prevalence of factor V: Q506 in 41 patients with isolated pulmonary embolism. Thromb Haemost 1997;77:440-443
128. Baglin TP, Brown K, Williamson D, Baker P, Luddington R. Relative risk of pulmonary embolism and deep vein thrombosis in association with the factor V Leiden mutation in a United Kingdom population. Thromb Haemost 1997;77:1219
129. Middeldorp S, Henkens CM, Koopman MM, et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998;128:15-20
130. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67
131. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85:1504-1508
132. Ridker PM, Glynn RJ, Miletich JP, et al. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med 1997;126:528-531
133. Svensson PJ, Zöller B, Dahlbäck B. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls. Thromb Haemost 1997;77:332-335
134. Svensson PJ, Zöller B, Mattiasson I, Dahlbäck B. The factor VR506Q mutation causing APC resistance is highly prevalent amongst unselected outpatients with clinically suspected deep venous thrombosis. J Intern Med 1997;241:379-385
135. Greengard JS, Eichinger S, Griffin JH, Bauer KA. Brief report: Variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg→Gln mutation in the gene for factor V. N Engl J Med 1994;331:1559-1562
136. Samama MM, Trossaert M, Horellou MH, et al. Risk of thrombosis in patients homozygous for factor V Leiden. Blood 1995;86:4700-4702
137. Martinelli I, Landi G, Merati G, et al. Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost 1996;75:393-394
138. Martinelli I, Sacchi E, Landi G, et al. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998;338:1793-1797
139. Holm J, Zöller B, Berntorp E, Erhardt L, Dahlbäck B. Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries. J Intern Med 1996;239:221-226
140. Rosendaal FR, Siscovick DS, Schwartz SM, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997;89:2817-2821
141. Doggen CJ, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: Increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998;97:1037-1041
142. Preston FE, Rosendaal FR, Walker ID, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996;348:913-916
143. Ridker PM, Miletich JP, Buring JE, et al. Factor V Leiden mutation as a risk factor lot recurrent pregnancy loss. Ann Intern Med 1998;128:1000-1003
144. Zöller B, He X, Dahlbäck B. Homozygous APC-resistance combined with inherited type I protein S deficiency in a young boy with severe thrombotic disease. Thromb Haemost 1995;73:743-745
145. Sifontes MT, Nuss R, Jacobson LJ, Griffin JH, Manco Johnson MJ. Thrombosis in otherwise well children with the factor V Leiden mutation. J Pediatr 1996:128:324-328
146. Kodish E, Potter C, Kirschbaum NE, Foster PA. Activated protein C resistance in a neonate with venous thrombosis. J Pediatr 1995;127:645-648
147. Nowak Göttl U, Schneppenheim R, Vielhaber H. APC resistance in childhood thromboembolism: Diagnosis and clinical aspects. Semin Thromb Hemost 1997;23:253-258
148. Nowak Göttl U, Vielhaber H, Grohmann J, Schneppenheim R. Koch HG. Arginine506 to glutamin mutation in the factor V gene in infancy and childhood: Evidence of fibrinolytic impairment. Eur J Pediatr 1997;156:195-198
149. Vandenbroucke JP, Helmerhorst FM, Bloemenkamp KW, Rosendaal FR. Third-generation oral contraceptive and deep venous thrombosis: From epidemiologic controversy to new insight in coagulation. Am J Obstet Gynecol 1997;177:887-891
150. World Health Organization Collaborative study of cardiovascular disease and steroid hormone contraception. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study. Lancet 1995;346:1582-1588
151. World Health Organization. Collaborative study of cardiovascular disease and steroid hormone contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346:1582-1588
152. Rosing J, Tans G, Nicolaes GA, et al. Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997;97:233-238
153. Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995;173:210-213
154. Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-1457
155. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995;346:1593-1596
156. Vandenbroucke JP, Rosendaal FR. End of the line for "third-generation-pill" controversy? Lancet 1997;349:1113-1114
157. Rintelen C, Mannhalter C, Ireland H, et al. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden. Br J Haematol 1996;93:487-490
158. Schambeck CM, Schwender S, Haubitz I, et al. Selective screening for the Factor V Leiden mutation: Is it advisable prior to the prescription of oral contraceptives? Thromb Haemost 1997;78:1480-1483
159. De Stefano V, Mastrangelo S, Paciaroni K, et al. Thrombotic risk during pregnancy and puerperium in women with APC-resistance - Effective subcutaneous heparin prophylaxis in a pregnant patient. Thromb Haemost 1995;74:793-794
160. Hallak M, Senderowicz J, Cassel A, et al. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Am J Obstet Gynecol 1997;176:889-893
161. Bokarewa MI, Bremme K, Blombäck M. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol 1996;92:473-478
162. McColl MD, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997;78:1183-1188
163. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995;332:993-997
164. Fijnheer R, Horbach DA, Donders RC, et al. Factor V Leiden, antiphospholipid antibodies and thrombosis in systemic lupus crythematosus. Thromb Haemost 1996;76:514-517
165. Davies KA, Ireland H, Athanassiou P, et al. Factor V Leiden mutation and venous thrombosis. Lancet 1995;345:132-133
166. Bengtsson A, Zöller B. Garcia de Frutos P, Dahlbäck B, Sturfelt G. Factor V: Q506 mutation and anticardiolipin antibodies in systemic lupus crythematosus. Lupus 1996;5:598-601
167. Sasso EH, Suzuki LA, Thompson AR, Petri MA. Hereditary resistance to activated protein C: An uncommon risk factor for thromboembolic disease in lupus patients with antiphospholipid antibodies. Arthritis Rheum 1997;40:1720-1721
168. Dizon Townson D, Hutchison C, Silver R, Branch DW, Ward K. The factor V Leiden mutation which predisposes to thrombosis is not common in patients with antiphospholipid syndrome. Thromb Haemost 1995;74:1029-1031
169. Miletich JP, Prescott SM, White R, Majerus PW, Bovill EG. Inherited predisposition to thrombosis. Cell 1993;72:477-480
170. Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994;84:1031-1035
171. Gandrille S, Greengard JS, Alhene Gelas M, et al. Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. The French Network on the behalf of INSERM. Blood 1995;86:219-224
172. Hallam PJ, Millar DS, Krawezak M, Kakkar VV, Cooper DN. Population differences in the frequency of the factor V Leiden variant among people with clinically symptomatic protein C deficiency. J Med Genet 1995;32:543-545
173. Zöller B, Berntsdotter A, Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995;85:3518-3523
174. Koeleman BP, van Rumpt D, Hamulyak K, Reitsma PH, Bertina RM. Factor V Leiden: An additional risk factor for thrombosis in protein S deficient families? Thromb Haemost 1995;74:580-583
175. van Boven HH, Reitsma PH, Rosendaal FR, et al. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost 1996;75:417-421
176. Zöller B, Svensson PJ, Dahlbäck B, Hillarp A. The A20210 allele of the prothrombin gene is frequently associated with the factor V Arg 506 to Gln mutation but not with protein S deficiency in thrombophilic families. Blood 1998;91:2210-2211
177. Zöller B, Berntsdotter A, García de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk facor in hereditary deficiency of protein S. Blood 1995;85:3518-3523
178. Hillarp A, Zöller B, Svensson PJ, Dahlbäck B. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost 1997;78:990-992
179. Rosendaal FR, Siscovick DS, Schwartz SM, et al. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997;90:1747-1750
180. Howard TE, Marusa M, Boisza J, Young A, et al. The prothrombin gent 3′-untranslated region mutation is frequently associated with factor V Leiden in thrombophilic patients and shows ethnic-specific variation in allele frequency. Blood 1998;91:1092
181. Ferraresi P, Marchetti G, Legnani C, et al. The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. Arterioscler Thromb Vasc Biol 1997;17:2418-2422
182. Zöller B, Svensson PJ, Dahlbäck B, Hillarp A. The A20210 allele of the prothrombin gene is frequently associated with the factor V Arg 506 to Gln mutation but not with protein S deficiency in thrombophilic families. Blood 1998;91:2210-2211
183. Makris M, Preston FE, Beauchamp NJ, et al. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost 1997;78:1426-1429
184. Ehrenforth S, Ludwig G, Klinke S, et al. The prothrombin 20210A allele is frequently coinherited in young carriers of the factor V Arg 506 to Gln mutation with venous thrombophilia. Blood 1998;91:2209-2210
185. Alhene Gelas M, Le Cam Duchez V, Emmerich J, et al. The A20210 allele of the prothrombin gene is not frequently associated with the factor V Arg 506 to Gln mutation in thrombophilic families. Blood 1997;90:1711
186. Miletich J, Sherman L, Broze G, Jr. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987;317:991-996
187. Tait RC, Walker ID, Reitsma PH, et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost 1995;73:87-93
188. Rosendaal FR. Risk factors for venous thrombosis: Prevalence, risk, and interaction. Semin Hematol 1997;34:171-187